• Explore /
  • Poster
  • / MC1923 phase II clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive-stage small cell lung cancer previously treated with chemotherapy and immunotherapy.

MC1923 phase II clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive-stage small cell lung cancer previously treated with chemotherapy and immunotherapy.

Abstract Poster

Authors

Konstantinos Leventakos

Konstantinos Leventakos

Department of Oncology, Mayo Clinic, Rochester, MN

Konstantinos Leventakos , Anastasios Dimou , Nathan R. Foster , Lynn M. Flickinger , Sri Harsha Tella , Julian R. Molina , Aaron Scott Mansfield , Randolph Marks , Anna J Schwecke , Craig Hocum , Jenesse Nicole Moffett , Ashley Potter , Alex A. Adjei

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04607954

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS8604)

DOI

10.1200/JCO.2022.40.16_suppl.TPS8604

Abstract #

TPS8604

Poster Bd #

222b

Abstract Disclosures

Similar Posters

First Author: Yuka Kato

Poster

2019 ASCO Annual Meeting

Phase II trial of carfilzomib and irinotecan in relapsed small cell lung cancer (NCT01941316).

Phase II trial of carfilzomib and irinotecan in relapsed small cell lung cancer (NCT01941316).

First Author: Susanne M. Arnold

First Author: Joachim Von Pawel

First Author: Benjamin Besse